TNDM - Tandem Diabetes Care, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 77.34 |
| Open | 76.87 |
| Bid | 79.20 x 1200 |
| Ask | 79.40 x 1100 |
| Day's Range | 75.26 - 80.68 |
| 52 Week Range | 43.69 - 92.37 |
| Volume | 1,542,140 |
| Avg. Volume | 1,236,003 |
| Market Cap | 4.77B |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings Date | Jul 30, 2020 - Aug 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.69 |
- Insider Monkey
Is Tandem Diabetes Care Inc (TNDM) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Business Wire
Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Kathleen McGroddy-Goetz, Ph.D., as an independent member of its Board of Directors effective June 8, 2020. Dr. McGroddy-Goetz has extensive experience commercializing pioneering technologies spanning from microelectronics through cloud, advanced data analytics, AI, hardware, software, and middleware with an emphasis on healthcare and life sciences applications.
- Zacks
Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis
Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).
- Zacks
Here's Why You Should Hold on to Tandem Diabetes Stock for Now
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.
- Business Wire
Tandem Diabetes Care Announces Upcoming Virtual Conference Presentations
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:
- Investor's Business Daily
Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely
Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.
- Thomson Reuters StreetEvents
Edited Transcript of TNDM earnings conference call or presentation 30-Apr-20 8:30pm GMT
Q1 2020 Tandem Diabetes Care Inc Earnings Call
- Business Wire
Tandem Diabetes Care to Hold Virtual-Only 2020 Annual Meeting of Stockholders
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders ("Annual Meeting") will be held in a virtual-only format due to continued public health concerns relating to COVID-19 and to prioritize the health and well-being of meeting participants. There is no change to the previously announced date and time of the meeting, which will be held on May 27, 2020 at 3:00pm Pacific Daylight Time.
- Motley Fool
2 Top Diabetes Stocks to Buy in May
These two diabetes companies have been beating the market all year long, but that’s not the only reason you should consider investing in them.
- Business Wire
Tandem Diabetes Care Announces Pricing of $250.0 Million of Convertible Senior Notes Due 2025
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem" or, the "Company") announced today the pricing of $250.0 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Tandem also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes. The sale of the Notes is expected to close on May 15, 2020, subject to customary closing conditions.
- Business Wire
Tandem Diabetes Care Announces Proposed Offering of $250.0 Million of Convertible Senior Notes Due 2025
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem" or, the "Company") announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Tandem also intends to grant to the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes.
- Benzinga
Cramer Gives His Opinion On Tandem Diabetes, JPMorgan And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Tandem Diabetes Care Inc (NASDAQ: TNDM) is heavily shorted. He finds that wrong, because the company had a great quarter. His favorite stock in the space is DexCom, Inc. (NASDAQ: DXCM).The tankers are traders and they don't necessarily offer a lot of value, said Cramer. He would be careful with Scorpio Tankers Inc. (NYSE: STNG).Cramer is not a buyer of LPL Financial Holdings Inc (NASDAQ: LPLA). He is not recommending any financial stocks at the moment.Carvana Co (NYSE: CVNA) has a very interesting business model, but it has to start to make money, said Cramer.JPMorgan Chase & Co. (NYSE: JPM) is an out-of-favor stock now, but it will be back in favor after the pandemic ends, said Cramer.Instead of CoStar Group Inc (NASDAQ: CSGP), Cramer would buy Mastercard Inc (NYSE: MA).See more from Benzinga * Cramer Shares His Thoughts On Slack, Archer Daniels Midland And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Zacks
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
- Motley Fool
Tandem Diabetes Care Inc (TNDM) Q1 2020 Earnings Call Transcript
TNDM earnings call for the period ending March 31, 2020.
- Business Wire
Tandem Diabetes Care Announces First Quarter 2020 Financial Results
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2020. In addition, due to the unknown depth and duration of the COVID-19 pandemic, the Company provided sales guidance for the second quarter 2020 and has withdrawn its financial guidance for the year ending December 31, 2020.
- Motley Fool
Will Tandem Diabetes Care Experience a COVID-19 Slowdown?
Investors might consider the company's products to be essential, but the business could face temporary problems getting products into the hands of new customers.
- Business Wire
Tandem Diabetes Care to Announce First Quarter 2020 Financial Results on April 30, 2020
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2020 results after the financial markets close on Thursday, April 30, 2020. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2020 financial and operating results.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Tandem Diabetes Care Inc (TNDM)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Investor's Business Daily
Stocks Showing Improving Market Leadership: Tandem Diabetes Care Earns 82 RS Rating
One stock that fits that bill is Tandem Diabetes Care, which had its Relative Strength (RS) Rating upgraded from 79 to 82 Thursday. While Tandem Diabetes Care is not near an ideal buying range right now, see if it manages to form and break out from a proper base. Tandem Diabetes Care earns the No. 21 rank among its peers in the Medical-Products industry group.
- Business Wire
Tandem Diabetes Care Announces Security Incident with Five Employee Email Accounts
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) today announced that it will be notifying its customers of an information security incident involving five Tandem employee email accounts.
- Thomson Reuters StreetEvents
Edited Transcript of TNDM earnings conference call or presentation 24-Feb-20 9:30pm GMT
Q4 2019 Tandem Diabetes Care Inc Earnings Call
- Business Wire
Tandem Diabetes Care Announces FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of its Basal-IQ™ technology as an interoperable automated glycemic controller (iAGC). This is the second system to receive iAGC designation by the FDA, following the Company’s clearance of the t:slim X2™ insulin pump with Control-IQ™ technology in December 2019.
- Investor's Business Daily
TNDM Stock Exit Preceded Stock Market Correction
This was a tough week as a stock market correction took hold. Here's how selling in stocks like TNDM stock allowed IBD's SwingTrader to sit out the fall.
- Simply Wall St.
Tandem Diabetes Care, Inc. Released Earnings Last Week And Analysts Lifted Their Price Target To US$94.00
It's been a sad week for Tandem Diabetes Care, Inc. (NASDAQ:TNDM), who've watched their investment drop 15% to...
- Investor's Business Daily
Leading Diabetes Outlet Flounders Despite Unexpected Profit As Sales Lag
Tandem Diabetes Care unexpectedly posted a fourth-quarter profit Monday, but TNDM stock slipped in after-hours action as sales came in lighter than expected. Guidance for 2020 was strong.
